| Literature DB >> 29159721 |
Mohamed Reda Aouad1,2, Mariem Mohammed Mayaba3, Arshi Naqvi3, Sanaa K Bardaweel4, Fawzia Faleh Al-Blewi3, Mouslim Messali3, Nadjet Rezki5,6.
Abstract
<span class="abstract_title">BACKGROUND: <span class="Chemical">1,2,4-Triazoles and 1,2,3-triazoles have gained significant importance in medicinal chemistry.Entities:
Keywords: 1,2,3-triazole-1,2,4-triazole hybrids; Antimicrobial activity; Click chemistry; Lipophilic side chain; Molecular docking
Year: 2017 PMID: 29159721 PMCID: PMC5696273 DOI: 10.1186/s13065-017-0347-4
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Scheme 1Synthesis of non-ionic surfactants based 1,2,3-triazole-4,5-diesters 3a–d
Scheme 2Synthesis of 1,2,3-triazole bis-1,2,4-triazole-3-thiones 6a–d
Scheme 3Synthesis of 1,2,3-triazole bis-4-amino-1,2,4-triazole-3-thiones 7a–d
Antimicrobial screening results of compounds 3–7(a–d) expressed as MIC defined as the least concentration that cause more than 80% growth inhibition of the microorganism (μg/mL)
| Compound no. | Gram-positive organisms | Gram-negative organisms | Fungi | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 256 | 512 | 512 | 128 | 256 | 512 | 512 | 256 |
|
| 128 | 512 | 256 | 128 | 128 | 512 | 512 | 256 |
|
| 64 | 256 | 128 | 64 | 128 | 256 | 256 | 128 |
|
| 64 | 256 | 128 | 64 | 64 | 256 | 256 | 128 |
|
| 128 | 256 | 128 | 64 | 128 | 256 | 256 | 128 |
|
| 64 | 256 | 64 | 64 | 128 | 256 | 256 | 128 |
|
| 64 | 128 | 64 | 32 | 64 | 128 | 64 | 64 |
|
| 32 | 128 | 64 | 16 | 32 | 128 | 64 | 32 |
|
| 32 | 128 | 64 | 32 | 64 | 256 | 128 | 64 |
|
| 32 | 128 | 32 | 32 | 32 | 128 | 128 | 32 |
|
| 16 | 64 | 32 | 16 | 32 | 64 | 32 | 16 |
|
| 8 | 64 | 16 | 8 | 16 | 64 | 32 | 16 |
|
| 16 | 64 | 32 | 16 | 16 | 128 | 32 | 8 |
|
| 16 | 64 | 16 | 16 | 16 | 64 | 32 | 8 |
|
| 4 | 32 | 8 | 8 | 8 | 32 | 16 | 4 |
|
| 4 | 32 | 4 | 4 | 4 | 32 | 16 | 2 |
|
| 8 | 32 | 16 | 8 | 8 | 64 | 16 | 4 |
|
| 8 | 16 | 8 | 8 | 8 | 64 | 16 | 4 |
|
| 2 | 16 | 4 | 4 | 4 | 32 | 8 | 2 |
|
| 2 | 8 | 1 | 2 | 1 | 16 | 8 | 1 |
| Ciprofloxacin | 4 | 8 | 1 | 4 | 1 | 8 | – | – |
| Fluconazole | – | – | – | – | – | – | 4 | 1 |
Bacillus cereus ATTC 10876 (B. cereus), Enterococcus faecalis ATTC 29212 (E. faecalis), Staphylococcus aureus ATTC 25923 (S. aureus)
Proteus mirabilis ATTC 35659 (P. mirabilis), Escherichia coli ATTC 25922 (E. coli), Pseudomonas aeruginosa ATTC 27853 (P. aeruginosa)
Candida albicans ATTC 50193 (C. albicans), Aspergillus brasiliensis ATTC 16404 (A. brasiliensis)
MIC minimum inhibitory concentration
Fig. 1Docking of some compounds 3a, 4a, 5a, 6d, 7d and standard drug ciprofloxacin into active site of glucosamine-6-phosphate (GlcN-6-P) synthase
Molecular docking results of the target compounds
| Compound no. | Minimum binding energy (kcal/mol) | Estimated inhibition constant, Ki = μM (micromolar), nM (nanomolar) |
|---|---|---|
|
| − 6.35 | 21.99 μM |
|
| − 5.72 | 63.71 μM |
|
| − 6.85 | 9.46 μM |
|
| − 6.61 | 14.20 μM |
|
| − 8.03 | 1.30 μM |
|
| − 7.67 | 2.40 μM |
|
| − 7.55 | 2.94 μM |
|
| − 6.88 | 9.04 μM |
|
| − 9.31 | 150.86 nM |
|
| − 7.92 | 1.57 μM |
|
| − 6.33 | 22.73 μM |
|
| − 6.27 | 25.31 μM |
|
| − 9.24 | 167.77 nM |
|
| − 9.77 | 69.47 nM |
|
| − 10.33 | 26.60 nM |
|
| − 10.49 | 20.57 nM |
|
| − 8.86 | 320.85 nM |
|
| − 9.27 | 159.60 nM |
|
| − 9.30 | 151.56 nM |
|
| − 9.23 | 170.12 nM |
| Ciprofloxacin | − 6.28 | 24.97 μM |